Blood microsampling: a model for the future

The US micro-sampling blood testing company Theranos was valued at nearly $9 billion. Forbes magazine reckons it's worth nothing now that the US Department of Health has imposed a two-year ban on the practice due to technical deficiencies. Although the Californian start-up is faltering, the microblood sampling model seems to be the one of the future.